# Lyumjev short acting now not covered by insurance

**URL:** https://forum.fudiabetes.org/t/lyumjev-short-acting-now-not-covered-by-insurance/15737
**Category:** Type 1 & LADA
**Tags:** insulin
**Created:** [January 7, 2026, 10:08pm UTC](https://forum.fudiabetes.org/t/lyumjev-short-acting-now-not-covered-by-insurance/15737 "2026-01-07T22:08:29Z")
**Posts on this page:** 1
**Showing post:** 11

<div class="post-metadata">

### Author: ![jbowler](https://avatars.discourse-cdn.com/v4/letter/j/e274bd/32.png) [@jbowler](https://forum.fudiabetes.org/u/jbowler)
#### Post date: [January 30, 2026, 6:06pm UTC](https://forum.fudiabetes.org/t/lyumjev-short-acting-now-not-covered-by-insurance/15737/11 "2026-01-30T18:06:04Z")

</div>

> [@squidsdc](#):
>
> the risk of occlusions in the X2 over the pain from Lyumjev

Pain suggests a site reaction, I can’t think of another explanation. This certainly occurs, e.g.:

[https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2023/insulin](https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2023/insulin)

Site reactions themselves are know to cause a reduction in insulin sensitivity with pumps certainly going back to 2010:

> **[Pilot Study for Assessment of Optimal Frequency for Changing Catheters in...](https://pmc.ncbi.nlm.nih.gov/articles/PMC2909532/)**
>
> Continuous subcutaneous insulin infusion (CSII) by means of insulin pump devices is considered to be one of the most optimal therapies to achieve treatment targets in patients with diabetes mellitus. In CSII, the insulin is delivered through Teflon...

There is a _lot_ of research between 2010 and today. The balance seems to be that the catheter (or, for Omnipod, the pod) can’t be relied on past 3 days and starts to fail at 2 days _but this varies enormously between diabetics_ In addition, as the first paper suggests, there is also _variation between insulins_.

So the idea that a particular insulin fails to work with a particular pump seems unlikely; Occam’s razor. We know that particular insulins fail with particular _people_! An endo will most likely respond to the information by swapping to a different but similar acting insulin. To me any demonstrable site reaction, including pain, seems a sure-fire reason to swap. If that means a formulary exception then I don’t imagine that would be hard though in the US the cost must also be considered.

This second link comes from this thread, which is also discussing site reactions and is certainly worth reading:

> [@Starting over with Omnipod 5](https://forum.fudiabetes.org/t/starting-over-with-omnipod-5/15766/4):
>
> Here’s an example of how corrections slowly work for me in Auto mode: That high BG at 5 pm was not looking like the algorithm could correct it, so 8u Aftezza and a soft landing 1 hour later. Then today at 170 after breakfast and the algorithm slowly correcting it. Decided to let it go (I was on the golf course so mildly exerting) and 3 hours later a soft landing.

---

_[View the full topic](https://forum.fudiabetes.org/t/lyumjev-short-acting-now-not-covered-by-insurance/15737)._